BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Holdings Raised by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 149.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,156 shares of the biotechnology company's stock after purchasing an additional 13,270 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in BioMarin Pharmaceutical were worth $2,136,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of BMRN. Vanguard Group Inc. boosted its stake in shares of BioMarin Pharmaceutical by 0.9% during the first quarter. Vanguard Group Inc. now owns 16,502,243 shares of the biotechnology company's stock valued at $1,272,322,000 after purchasing an additional 151,212 shares during the period. Barclays PLC boosted its position in BioMarin Pharmaceutical by 31.6% in the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company's stock valued at $493,111,000 after buying an additional 1,336,886 shares during the last quarter. Ameriprise Financial Inc. boosted its position in BioMarin Pharmaceutical by 5.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company's stock worth $456,906,000 after purchasing an additional 275,436 shares in the last quarter. Norges Bank purchased a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $285,013,000. Finally, Geode Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical by 3.0% during the 1st quarter. Geode Capital Management LLC now owns 2,662,123 shares of the biotechnology company's stock valued at $258,492,000 after buying an additional 78,019 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on BMRN shares. Royal Bank of Canada reissued a "sector perform" rating and issued a $100.00 price objective on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Stifel Nicolaus reaffirmed a "buy" rating and issued a $101.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, December 21st. Cantor Fitzgerald reissued an "overweight" rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Robert W. Baird lowered their price target on BioMarin Pharmaceutical from $127.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, January 30th. Finally, Piper Sandler reduced their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $107.61.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ:BMRN traded up $0.11 during trading on Thursday, reaching $86.89. 1,151,883 shares of the stock were exchanged, compared to its average volume of 1,314,897. BioMarin Pharmaceutical Inc. has a 12 month low of $76.02 and a 12 month high of $100.38. The firm has a market cap of $16.39 billion, a PE ratio of 98.74, a PEG ratio of 1.66 and a beta of 0.31. The stock has a 50-day moving average price of $87.55 and a 200-day moving average price of $89.00. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $646.21 million during the quarter, compared to analysts' expectations of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The company's quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.11 earnings per share. Research analysts expect that BioMarin Pharmaceutical Inc. will post 1.92 EPS for the current fiscal year.

Insider Activity

In related news, Director Jean Jacques Bienaime sold 10,000 shares of the firm's stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $98.19, for a total value of $981,900.00. Following the transaction, the director now owns 425,162 shares of the company's stock, valued at approximately $41,746,656.78. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $98.19, for a total value of $981,900.00. Following the completion of the transaction, the director now directly owns 425,162 shares in the company, valued at approximately $41,746,656.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the transaction, the insider now owns 212,117 shares of the company's stock, valued at $18,068,126.06. The disclosure for this sale can be found here. Insiders sold a total of 90,943 shares of company stock worth $8,013,927 in the last three months. Company insiders own 1.84% of the company's stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.